100 tracked 13F filers disclose a position in KALV as of the latest SEC 13F filings, a combined $935.6M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Venrock Adviser, LLC | $130.3M | 6.5M | ▼−3.8% Reduced · −255K sh | Q1 2026 | |
| 2 | MONTANOVA CAPITAL, LLC | $96.0M | 4.8M | —Held | Q1 2026 | |
| 3 | TANG CAPITAL MANAGEMENT LLC | $92.1M | 4.6M | —Held | Q1 2026 | |
| 4 | BlackRock, Inc. | $76.4M | 3.8M | ▲+1.1% Added · +42K sh | Q1 2026 | |
| 5 | Point72 Asset Management, L.P. | $43.0M | 2.1M | ▼−6.4% Reduced · −147K sh | Q1 2026 | |
| 6 | MILLENNIUM MANAGEMENT LLC | $38.5M | 1.9M | ▼−34% Reduced · −985K sh | Q1 2026 | |
| 7 | Vestal Point Capital, LP | $37.2M | 1.9M | ▼−2.1% Reduced · −40K sh | Q1 2026 | |
| 8 | Parkman Healthcare Partners LLC | $36.9M | 1.8M | ▲+3.8% Added · +67K sh | Q1 2026 | |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $36.8M | 1.8M | →First observed position No prior filed position | Q1 2026 | |
| 10 | Kynam Capital Management, LP | $36.7M | 1.8M | ▲+0.6% Added · +10K sh | Q1 2026 | |
| 11 | Woodline Partners LP | $30.4M | 1.5M | ▼−21% Reduced · −411K sh | Q1 2026 | |
| 12 | Octagon Capital Advisors LP | $29.2M | 1.4M | ▲+14% Added · +177K sh | Q1 2026 | |
| 13 | ARMISTICE CAPITAL, LLC | $24.9M | 1.2M | ▲+55% Added · +436K sh | Q1 2026 | |
| 14 | Squadron Capital Management LLC | $19.8M | 985K | ▲+41% Added · +285K sh | Q1 2026 | |
| 15 | Freestone Grove Partners LP | $17.8M | 883K | ▲+39% Added · +250K sh | Q1 2026 | |
| 16 | GOLDMAN SACHS GROUP INC | $16.6M | 824K | ▼−1.3% Reduced · −11K sh | Q1 2026 | |
| 17 | GREAT POINT PARTNERS LLC | $13.6M | 675K | ▼−1.6% Reduced · −11K sh | Q1 2026 | |
| 18 | Bank of New York Mellon Corp | $11.8M | 584K | ▼−16% Reduced · −111K sh | Q1 2026 | |
| 19 | BANK OF AMERICA CORP /DE/ | $11.2M | 556K | ▲+43% Added · +166K sh | Q1 2026 | |
| 20 | BARCLAYS PLC | $10.8M | 537K | ▼−23% Reduced · −164K sh | Q1 2026 | |
| 21 | UBS Group AG | $10.4M | 516K | ▲+39% Added · +144K sh | Q1 2026 | |
| 22 | SCHRODER INVESTMENT MANAGEMENT GROUP | $9.3M | 507K | ▼−57% Reduced · −665K sh | Q1 2026 | |
| 23 | MORGAN STANLEY | $8.8M | 439K | ▼−37% Reduced · −261K sh | Q1 2026 | |
| 24 | NORTHERN TRUST CORP | $7.3M | 364K | ▲+3.3% Added · +12K sh | Q1 2026 | |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | $7.3M | 363K | →First observed position No prior filed position | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 9 funds opened a new position in KALV and 21 added to an existing one, while 14 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| INTUITIVE SURGICAL INCISRG | 40 funds | $16.1B |
| BRISTOL-MYERS SQUIBB COBMY | 40 funds | $8.0B |
| CYTOKINETICS INCCYTK | 39 funds | $855.8M |
| MICROSOFT CORPMSFT | 38 funds | $138.1B |
| ELI LILLY & COLLY | 38 funds | $41.2B |
| UNITEDHEALTH GROUP INCUNH | 38 funds | $15.9B |
| STRYKER CORPSYK | 38 funds | $9.4B |
| BOSTON SCIENTIFIC CORPBSX | 38 funds | $7.2B |
| REGENERON PHARMACEUTICALSREGN | 38 funds | $7.1B |
| COGENT BIOSCIENCES INCCOGT | 38 funds | $1.2B |
| NVIDIA CORPNVDA | 37 funds | $206.4B |
| AMAZON.COM INCAMZN | 37 funds | $96.7B |
Ranked by how many of KALV's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell (S) | 34K | $905K |
| May 26, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell (S) | 2K | $60K |
| May 26, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell (S) | 2K | $53K |
| May 26, 2026 | Sweeny Nicole | Chief Commercial Officer | Sell (S) | 1K | $40K |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell (S) | 3K | $72K |
| May 22, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER, Director | Sell (S) | 11K | $293K |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell (S) | 2K | $63K |
| May 22, 2026 | Piekos Brian | Chief Financial Officer | Sell (S) | 1K | $40K |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | Sell (S) | 2K | $50K |
| May 18, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell (S) | 1K | $28K |
| May 18, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER, Director | Sell (S) | 1K | $30K |
| May 18, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell (S) | 1K | $30K |
Connected entities for KALV
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/KALV/capital-change-brief"
Use Arkolith's capital_change_brief for KALV. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for KALV. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.